TAC 302

Drug Profile

TAC 302

Alternative Names: TAC 302

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Urologics
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Overactive bladder

Most Recent Events

  • 01 Aug 2017 Phase-II clinical trials in Overactive bladder in Japan (PO) (NCT03175029)
  • 12 Jun 2017 Taiho Pharmaceutical plans a phase II trial for Overactive bladder in Japan (NCT03175029)
  • 12 Jun 2017 Preclinical trials in Bladder dysfunction in Japan (PO) before June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top